HC Wainwright Reiterates “Buy” Rating for Avadel Pharmaceuticals (NASDAQ:AVDL)

HC Wainwright reiterated their buy rating on shares of Avadel Pharmaceuticals (NASDAQ:AVDL) in a research note published on Tuesday morning,Benzinga reports. The brokerage currently has a $21.00 price objective on the stock. HC Wainwright also issued estimates for Avadel Pharmaceuticals’ Q3 2025 earnings at $0.01 EPS and Q4 2025 earnings at $0.12 EPS.

Several other equities analysts have also recently issued reports on AVDL. Piper Sandler decreased their price objective on Avadel Pharmaceuticals from $24.00 to $13.00 and set an “overweight” rating for the company in a report on Friday, January 10th. Deutsche Bank Aktiengesellschaft started coverage on Avadel Pharmaceuticals in a report on Tuesday, February 11th. They issued a “buy” rating and a $12.00 price target for the company. Needham & Company LLC restated a “buy” rating and issued a $19.00 price objective on shares of Avadel Pharmaceuticals in a research report on Monday. Finally, UBS Group cut their target price on shares of Avadel Pharmaceuticals from $22.00 to $14.00 and set a “buy” rating for the company in a report on Monday, January 13th. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $19.88.

Avadel Pharmaceuticals Price Performance

NASDAQ AVDL opened at $7.88 on Tuesday. Avadel Pharmaceuticals has a 1 year low of $7.39 and a 1 year high of $19.09. The company has a market capitalization of $759.33 million, a PE ratio of -9.97 and a beta of 1.28. The company has a fifty day moving average of $8.67 and a 200 day moving average of $11.45.

Insider Buying and Selling at Avadel Pharmaceuticals

In related news, Director Peter J. Thornton acquired 10,000 shares of Avadel Pharmaceuticals stock in a transaction on Monday, January 13th. The stock was bought at an average cost of $8.04 per share, for a total transaction of $80,400.00. Following the completion of the transaction, the director now owns 104,055 shares of the company’s stock, valued at approximately $836,602.20. The trade was a 10.63 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Thomas S. Mchugh bought 5,000 shares of the company’s stock in a transaction dated Wednesday, December 11th. The stock was bought at an average price of $10.49 per share, for a total transaction of $52,450.00. Following the transaction, the chief financial officer now owns 85,500 shares of the company’s stock, valued at approximately $896,895. This trade represents a 6.21 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders have acquired 42,981 shares of company stock valued at $400,005. Company insiders own 4.80% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. PVG Asset Management Corp purchased a new stake in Avadel Pharmaceuticals during the 4th quarter worth approximately $358,000. Two Seas Capital LP boosted its stake in shares of Avadel Pharmaceuticals by 90.6% in the fourth quarter. Two Seas Capital LP now owns 4,296,449 shares of the company’s stock worth $45,156,000 after acquiring an additional 2,042,669 shares during the last quarter. Zimmer Partners LP acquired a new stake in shares of Avadel Pharmaceuticals in the fourth quarter worth approximately $420,000. Tang Capital Management LLC increased its position in shares of Avadel Pharmaceuticals by 21.7% during the fourth quarter. Tang Capital Management LLC now owns 1,497,500 shares of the company’s stock worth $15,739,000 after purchasing an additional 267,500 shares in the last quarter. Finally, ProShare Advisors LLC raised its stake in Avadel Pharmaceuticals by 32.1% in the 4th quarter. ProShare Advisors LLC now owns 30,592 shares of the company’s stock valued at $322,000 after purchasing an additional 7,433 shares during the last quarter. 69.19% of the stock is owned by hedge funds and other institutional investors.

Avadel Pharmaceuticals Company Profile

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.